查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1235934

癌症登記軟件市場：到 2028 年的預測——按類型、數據庫類型、功能、部署模型、最終用戶和地區進行的全球分析

Cancer Registry Software Market Forecasts to 2028 - Global Analysis By Type, Database Type, Functionality, Deployment Model, End User and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2022 年全球癌症登記軟件市場規模將達到 597.2 億美元，預計到 2028 年將達到 1123.2 億美元，根據預測期預計將以期間複合年增長率為 11.1%

癌症登記軟件可自動收集國家和州登記處的數據，並有助於跟蹤不同治療方案的有效性。 此外，國家登記處收集的數據有助於我們更好地了解和治療疾病。 收集的信息對於識別風險因素很重要，例如環境風險，如煙草使用、陽光照射、化學品和輻射暴露。 還需要這些數據來遵循篩查和治療方案，並確定可以在哪些方面進行改進。 此外，登記數據有助於研究機構衡量癌症管理、治療和預防計劃的有效性。

根據 Proteus Breach 的數據，2019 年醫療保健行業有 4140 萬條患者記錄遭到破壞，數量驚人。

市場動態。

驅動程序

癌症患者的患病率增加

乳腺癌、宮頸癌和前列腺癌是美國和歐洲人群中最常見的癌症。 為了解趨勢並確定原因，醫學研究人員需要有關癌症的最新數據，包括診斷出患有癌症的人口、接受治療的患者人數和死亡率。 醫療保健從業者需要癌症發病率統計數據來幫助確定需要購買多少設備和藥物來進行治療和提高認識。 在預測期內，越來越多地利用癌症登記處收集、存儲和管理數據將對市場焦點產生積極影響。

約束

數據隱私和安□□全

由於該系統收集高度個人化的數據，數據隱私和安□□全問題將成為預測期內癌症登記軟件市場的主要障礙。 癌症登記處收集患者人口統計數據、腫瘤特徵、治療和疾病結果等信息。 政府機構專注於執行新的法規和法律，以確保信息的安全管理。 《健康保險流通與責任法案》和美國衛生與公眾服務部 (HHS) 還列出了各種有關消費者健康數據保護和隱私的聯邦法規。

機會

腫瘤學臨床研究的增加

製藥公司和研究機構正在進行臨床試驗，以開發新的癌症治療技術。 在臨床試驗和研究期間對註冊數據進行深入分析有助於確定癌症原因和治療方法，以便更好地進行監測。 癌症登記被研究機構和製藥公司用作 III 期和 IV 期臨床研究的後續材料。 開發複雜的癌症登記軟件有助於提高公共和私人癌症登記處的數據質量。 這將有助於未來幾年市場的擴張。

威脅

缺乏互操作性/集成

EHR 系統與獨立癌症登記軟件之間缺乏連通性阻礙了新替代品的開發。 預計此類數據交換問題將需要人工干預，以在不同 EHR 系統之間導入或導出患者記錄，直到建立跨國家和地區的通用健康信息交換系統。 因此，不完全兼容的 EHR 的廣泛採用給癌症患者登記軟件供應商帶來了重大問題。

COVID-19 的影響

由於 COVID-19 大流行，癌症診斷在大流行期間顯著下降，化療、手術和其他輔助癌症治療也是如此。 醫生要求我在內窺鏡切除術後、手術切除術後和息肉切除術後推遲癌症治療。 它還建議推遲對感染風險高的癌症患者進行篩查，從而減少治療工作。 政府承諾未來資助註冊業務作為疾病控制資產，並轉向電子報告系統，可以確保癌症監測領域的可持續性。

預計在預測期內集成軟件部分將成為最大的部分

由於對軟件與區域腫瘤學網絡的集成需求不斷增加，預計集成軟件部分將實現利潤豐厚的增長。 這可能有助於跟蹤受影響區域的地理位置並評估治療干預措施。 它還有助於收集有關疾病負擔的數據和治療方案的成功。 此外，需要與篩查檔案合作，以識別篩查檢測到的癌症並改進評估程序。 這些因素預計將在未來幾年推動這一領域的擴張。

預計商業數據庫領域在預測期內的複合年增長率最高

由於與公共數據庫相比，商業數據庫具有更高的數據安全性優勢，因此預計在預測期內將以最快的複合年增長率增長。 商業數據庫符合大多數聯邦政府的要求和規範。 此外，數據結構化且易於跟蹤。 商業技術使疾病控制和預防中心 (CDC) 等政府研究機構與中央癌症登記處之間的數據傳輸成為可能。

市場份額最大的地區

由於基礎設施發達，預計北美在預測期內將佔據最大的市場份額。 該地區先進的基礎設施和不斷增加的創新研發投資是推動癌症登記軟件市場增長的關鍵因素。 根據美國國立衛生研究院 (NIH) 的數據，癌症是美國第二大死因。 在該地區，由於吸煙和缺乏運動等因素導致的癌症發病率正在增加，這推動了市場的擴張。

複合年增長率最高的地區。

由於政府舉措的增加，預計亞太地區在預測期內的複合年增長率最高。 在日本，厚生勞動省正在啟動一個項目，以加強該國的醫療保健基礎設施。 在中國，第十二個五年計劃宣佈建立區域醫療保健信息網絡 (RHIN)。 此外，製藥業務向中國和印度等低成本製造國家的轉移正在推動亞太行業向前發展。

取得了重大進展。

2022 年 3 月，Elekta 宣布國家衛生服務供應鏈 (NHSSC) 將訂購 Elekta ProKnow 軟件解決方案的多個許可，以在安全且高度可擴展的平台上集中管理和分析放射治療數據。NHS England (NHSE) 輻射腫瘤科設施現已開放。

2018 年 11 月，Onco 升級了 OncoLog 版本 4.4.0，以包含 NAACCR、AJCC、CoC 和 SEER 規定的最新要求。

我們的報告提供了什麼

  • 區域和國家級細分市場的市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場驅動因素（市場趨勢、制約因素、機遇、威脅、挑戰、投資機會、建議等）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局和趨勢
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 供應鏈趨勢反映了最新的技術進步。

提供免費定制

購買此報告的客戶將免費獲得以下定制之一。

  • 公司簡介
    • 對其他市場參與者（最多 3 個）進行全面分析
    • 關鍵參與者的 SWOT 分析（最多 3 名參與者）
  • 區域細分
    • 根據客戶要求提供主要國家/地區的市場估算、預測和復合年增長率（注意：不包括可行性檢查。）
  • 競爭基準
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究信息來源
    • 二手研究資源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球癌症登記軟件市場：按類型

  • 獨立軟件
  • 集成軟件

第 6 章全球癌症登記軟件市場：按數據庫類型

  • 公共數據庫
  • 商業數據庫

第 7 章全球癌症登記軟件市場：按功能分類

  • 產品性能評估
  • 符合州和聯邦法規的癌症報告
  • 醫學研究和臨床研究
  • 患者護理管理

第 8 章全球癌症登記軟件市場：按部署模型

  • 基於雲
  • 本地

第 9 章全球癌症登記軟件市場：按最終用戶分類

  • 研究中心
  • 醫院和醫療機構
  • 個人付款人
  • 製藥、生物技術和醫療設備公司
  • 政府機構和第三方管理員

第 10 章全球癌症登記軟件市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東地區

第11章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • IBM Corporation
  • McKesson Corporation
  • Himagine Solutions Inc.
  • CONDUENT Inc.
  • C/Net Solutions
  • Elekta AB
  • Rocky Mountain Cancer Data Systems
  • Ordinal Data Inc.
  • Electronic Registry Systems Inc.
  • Onco Inc.
  • F. Hoffmann-La Roche Ltd
  • Netdox Health Pvt. Ltd.
  • Centers for Disease Control and Prevention
Product Code: SMRC22531

According to Stratistics MRC, the Global Cancer Registry Software Market is accounted for $59.72 billion in 2022 and is expected to reach $112.32 billion by 2028 growing at a CAGR of 11.1% during the forecast period. The cancer registry software automates data collecting for national and state registries, which aids in tracking the effectiveness of various treatment regimens. Furthermore, the data collected by the state registries aid in better understanding and treatment of the condition. The information gathered is critical in identifying risk factors such as tobacco usage, sun exposure, or environmental risks such as chemical and radiation exposure. This data is also required for determining where screening and treatment options should be tracked and improved. Furthermore, registry data can help research institutes measure the effectiveness of cancer management, treatment, and preventive programmes.

According to Proteus Breach, healthcare sector saw a massive 41.4 million patient records breached in 2019.

Market Dynamics:

Driver:

Growing prevalence of cancer cases

Breast, cervical, and prostate cancers are extremely common in the populations of the United States and Europe. To track trends and examine the possible causes of cancer, medical researchers require up-to-date data on cancer, such as the population diagnosed with cancer, patients undergoing treatment, and mortality rate. Healthcare professionals require cancer incidence statistics in order to make judgements about the amount of equipment and drugs to purchase for treatment and awareness. The increased usage of cancer registry systems for data collecting, storage, and management would have a favourable impact on the market focus during the projection period.

Restraint:

Data privacy and security

Data privacy and security issues, as the system collects highly personal data, will be a major barrier for the cancer registry software market over the projection period. Cancer registries collect information such as patient demographics, tumour features, treatment, and disease outcome. Government agencies are concentrating on the implementation of new regulations and laws to ensure the safe management of information. Various federal regulations are also listed in the Health Insurance Portability and Accountability Act and the US Department of Health and Human Services (HHS) for the protection and privacy of consumer health data.

Opportunity:

Increasing clinical research for oncology

Clinical trials are being conducted by pharmaceutical companies and research organisations in order to develop novel cancer treatment techniques. Clinical trials and in-depth analyses of registry data during clinical research aid in the identification of proper monitoring of cancer causes and therapies. Cancer registries are used by research institutes and pharmaceutical corporations as a follow-up source during phase III and phase IV clinical studies. The development of sophisticated cancer registry software assists public and private cancer registry organisations in improving data quality. This will help the market's expansion in the coming years.

Threat:

Lack of interoperability and integration

The lack of connectivity between EHR systems and independent cancer patient registration software has impeded the development of novel alternatives. These types of data exchange problems are expected to continue to necessitate manual methods for importing or exporting patient records between different EHR systems until a universal health information exchange system is built throughout a country/region. As a result, broad adoption of EHRs that are not fully compatible poses a significant problem for cancer patient registry software suppliers.

COVID-19 Impact

Because of the COVID-19 pandemic, cancer diagnoses declined considerably during the pandemic, as did chemotherapy, surgery, and other supporting cancer treatments. Doctors were urged to postpone post-endoscopic resection, surgical resection of cancer, and post-polypectomy cancer. They also recommended that screening for high-risk cancer patients be postponed due to the risk of infection, which resulted in a reduction in treatment operations. A government commitment to fund future registry operations as a disease control asset, along with a shift towards electronic reporting systems, would help to secure the global sustainability of cancer surveillance.

The integrated software segment is expected to be the largest during the forecast period

The integrated software segment is estimated to have a lucrative growth, due to the increasing demand for integrating software with a regional oncology network. This will aid in tracking affected geographic locations and evaluating the treatment intervention. It will also contribute in the collection of data on illness burden and the success of treatment programmes. Furthermore, linkage with screening archives is required to identify screen-detected cancers and improve evaluation procedures. These factors are projected to drive the expansion of this segment in the next years.

The commercial database segment is expected to have the highest CAGR during the forecast period

The commercial database segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its advantage of data safety as compared to the public database. The commercial database complies with most federal requirements and codes. The data is also well-structured and simple to follow. Commercial technologies enable data transmission among government research agencies such as the Centers for Disease Control and Prevention (CDC) and central cancer registries.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of developed infrastructure. The region's advanced infrastructure and increased investment in research & development for innovation are important factors driving the growth of the cancer registry software market. Cancer is the second highest cause of mortality in the United States, according to the National Institutes of Health (NIH). The rising incidence of cancer in this region, owing to cigarette use and a lack of physical exercise, among other factors, is fuelling market expansion.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to increasing government initiatives being undertaken in this region. In Japan, the Ministry of Health, Labour, and Welfare has launched projects to strengthen the country's healthcare infrastructure. China has also unveiled its 12th Five-Year Plan to improve the country's Regional Healthcare Information Networks (RHINs). Furthermore, the movement of pharmaceutical businesses to low-cost manufacturing countries such as China and India is moving the Asia Pacific industry forward.

Key players in the market

Some of the key players profiled in the Cancer Registry Software Market include: IBM Corporation, McKesson Corporation, Himagine Solutions Inc., CONDUENT Inc., C/Net Solutions, Elekta AB, Rocky Mountain Cancer Data Systems, Ordinal Data Inc., Electronic Registry Systems Inc., Onco Inc., F. Hoffmann-La Roche Ltd, Netdox Health Pvt. Ltd. and Centers for Disease Control and Prevention

Key Developments:

In March 2022, Elekta stated that National Health Service Supply Chain (NHSSC) had ordered multiple licenses for Elekta's ProKnow software solution, which centralizes and analyzes radiotherapy data in a secure, scalable platform, accessible to the NHS England's (NHSE's) radiation oncology facilities throughout the country.

In November 2018, Onco upgraded the OncoLog Version 4.4.0 to include the newest requirements mandated by NAACCR, AJCC, CoC and SEER.

Types Covered:

  • Standalone Software
  • Integrated Software

Database Types Covered:

  • Public Database
  • Commercial Database

Functionalities Covered:

  • Product Outcome Evaluation
  • Cancer Reporting to Meet State and Federal Regulations
  • Medical Research & Clinical Studies
  • Patient Care Management

Deployment Models Covered:

  • Cloud-based
  • On-premise

End Users Covered:

  • Research Centre
  • Hospitals & Medical Practices
  • Private Payers
  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Government Organizations & Third-Party Administrators

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Registry Software Market, By Type

  • 5.1 Introduction
  • 5.2 Standalone Software
  • 5.3 Integrated Software

6 Global Cancer Registry Software Market, By Database Type

  • 6.1 Introduction
  • 6.2 Public Database
  • 6.3 Commercial Database

7 Global Cancer Registry Software Market, By Functionality

  • 7.1 Introduction
  • 7.2 Product Outcome Evaluation
  • 7.3 Cancer Reporting to Meet State and Federal Regulations
  • 7.4 Medical Research & Clinical Studies
  • 7.5 Patient Care Management

8 Global Cancer Registry Software Market, By Deployment Model

  • 8.1 Introduction
  • 8.2 Cloud-based
  • 8.3 On-premise

9 Global Cancer Registry Software Market, By End User

  • 9.1 Introduction
  • 9.2 Research Centre
  • 9.3 Hospitals & Medical Practices
  • 9.4 Private Payers
  • 9.5 Pharmaceutical, Biotechnology, and Medical Device Companies
  • 9.6 Government Organizations & Third-Party Administrators

10 Global Cancer Registry Software Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 IBM Corporation
  • 12.2 McKesson Corporation
  • 12.3 Himagine Solutions Inc.
  • 12.4 CONDUENT Inc.
  • 12.5 C/Net Solutions
  • 12.6 Elekta AB
  • 12.7 Rocky Mountain Cancer Data Systems
  • 12.8 Ordinal Data Inc.
  • 12.9 Electronic Registry Systems Inc.
  • 12.10 Onco Inc.
  • 12.11 F. Hoffmann-La Roche Ltd
  • 12.12 Netdox Health Pvt. Ltd.
  • 12.13 Centers for Disease Control and Prevention

List of Tables

  • Table 1 Global Cancer Registry Software Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
  • Table 3 Global Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
  • Table 4 Global Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
  • Table 5 Global Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
  • Table 6 Global Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
  • Table 7 Global Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
  • Table 8 Global Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
  • Table 9 Global Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
  • Table 10 Global Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
  • Table 11 Global Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
  • Table 12 Global Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
  • Table 13 Global Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
  • Table 14 Global Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
  • Table 15 Global Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
  • Table 16 Global Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
  • Table 17 Global Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
  • Table 18 Global Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
  • Table 19 Global Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
  • Table 20 Global Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
  • Table 21 Global Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
  • Table 22 North America Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
  • Table 23 North America Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
  • Table 24 North America Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
  • Table 25 North America Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
  • Table 26 North America Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
  • Table 27 North America Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
  • Table 28 North America Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
  • Table 29 North America Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
  • Table 30 North America Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
  • Table 31 North America Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
  • Table 32 North America Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
  • Table 33 North America Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
  • Table 34 North America Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
  • Table 35 North America Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
  • Table 36 North America Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
  • Table 37 North America Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
  • Table 38 North America Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
  • Table 39 North America Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
  • Table 40 North America Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
  • Table 41 North America Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
  • Table 42 North America Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
  • Table 43 Europe Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
  • Table 44 Europe Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
  • Table 45 Europe Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
  • Table 46 Europe Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
  • Table 47 Europe Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
  • Table 48 Europe Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
  • Table 49 Europe Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
  • Table 50 Europe Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
  • Table 51 Europe Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
  • Table 52 Europe Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
  • Table 53 Europe Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
  • Table 54 Europe Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
  • Table 55 Europe Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
  • Table 56 Europe Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
  • Table 57 Europe Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
  • Table 58 Europe Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
  • Table 59 Europe Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
  • Table 60 Europe Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
  • Table 61 Europe Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
  • Table 62 Europe Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
  • Table 63 Europe Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
  • Table 64 Asia Pacific Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
  • Table 65 Asia Pacific Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
  • Table 66 Asia Pacific Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
  • Table 67 Asia Pacific Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
  • Table 68 Asia Pacific Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
  • Table 69 Asia Pacific Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
  • Table 70 Asia Pacific Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
  • Table 71 Asia Pacific Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
  • Table 72 Asia Pacific Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
  • Table 73 Asia Pacific Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
  • Table 74 Asia Pacific Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
  • Table 75 Asia Pacific Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
  • Table 76 Asia Pacific Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
  • Table 77 Asia Pacific Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
  • Table 78 Asia Pacific Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
  • Table 79 Asia Pacific Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
  • Table 80 Asia Pacific Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
  • Table 81 Asia Pacific Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
  • Table 82 Asia Pacific Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
  • Table 83 Asia Pacific Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
  • Table 84 Asia Pacific Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
  • Table 85 South America Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
  • Table 86 South America Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
  • Table 87 South America Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
  • Table 88 South America Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
  • Table 89 South America Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
  • Table 90 South America Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
  • Table 91 South America Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
  • Table 92 South America Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
  • Table 93 South America Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
  • Table 94 South America Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
  • Table 95 South America Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
  • Table 96 South America Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
  • Table 97 South America Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
  • Table 98 South America Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
  • Table 99 South America Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
  • Table 100 South America Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
  • Table 101 South America Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
  • Table 102 South America Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
  • Table 103 South America Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
  • Table 104 South America Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
  • Table 105 South America Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
  • Table 106 Middle East & Africa Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
  • Table 107 Middle East & Africa Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
  • Table 108 Middle East & Africa Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
  • Table 109 Middle East & Africa Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
  • Table 110 Middle East & Africa Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
  • Table 111 Middle East & Africa Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
  • Table 112 Middle East & Africa Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
  • Table 113 Middle East & Africa Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
  • Table 114 Middle East & Africa Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
  • Table 115 Middle East & Africa Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
  • Table 116 Middle East & Africa Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
  • Table 117 Middle East & Africa Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
  • Table 118 Middle East & Africa Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
  • Table 119 Middle East & Africa Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
  • Table 120 Middle East & Africa Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
  • Table 121 Middle East & Africa Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
  • Table 122 Middle East & Africa Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
  • Table 123 Middle East & Africa Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
  • Table 124 Middle East & Africa Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
  • Table 125 Middle East & Africa Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
  • Table 126 Middle East & Africa Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)